Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

now accounting for more than a third of its total sales there has been pressure on the company to diversify. Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular ...

At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum ...

This has allowed the company to capitalize on the rising demand for advanced AI chips, supported by its strong presence in thin-film solutions. Additionally, Merck is divesting its Surface ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still ...

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $111.88, a 25.38% upside from current levels. In a report released on March 28, Leerink Partners also ...

In the latest market close, Merck (MRK) reached $94.71, with a +1.46% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and ...